TYK2 (tyrosine kinase 2) is a member of the Janus kinase family. It sits inside your cells and carries the signals from IL-23 and IL-12 — the two messengers that drive the psoriasis inflammation cascade — from the cell surface to the nucleus.
What makes deucravacitinib different from a conventional JAK inhibitor is where it binds. Ordinary JAK inhibitors plug the active site of the enzyme, the part that does the work. That active site looks nearly identical across JAK1, JAK2, JAK3 and TYK2, which is why those drugs hit several JAKs at once and produce broad immune suppression, falling blood counts and the class boxed warning.
Deucravacitinib binds a completely different part of the enzyme — a regulatory region called the pseudokinase domain, which is structurally distinctive to TYK2. Locking that region holds the enzyme in an off state without touching JAK1, JAK2 or JAK3 at normal doses.
The practical consequence is the entire reason to consider this drug. Because JAK1 and JAK2 keep working, your blood counts do not fall, your cholesterol does not climb the way it does on a JAK inhibitor, and the FDA did not apply the class boxed warning. You get an oral drug for psoriasis with a safety profile closer to a biologic than to Rinvoq.
The trade-off is potency. Blocking one narrow pathway is safer and less powerful than blocking many.
There is no meaningful interaction with alcohol, no photosensitivity, and no long list of drug interactions of the sort that complicate JAK inhibitors. If you have diabetes, be aware that hypoglycemia has been reported after starting JAK-family inhibitors — tell your prescriber and watch for low-sugar symptoms in the early weeks.
Monitoring on Sotyktu is genuinely lighter than on the oral JAK inhibitors, and that is one of the real reasons to choose it. But it is not zero.
Before you start: a tuberculosis test — a blood test such as QuantiFERON, or a skin test — with a chest X-ray if it is positive or you have risk factors. Active TB rules the drug out; latent TB is treated first. Complete all age-appropriate immunizations, including live vaccines and, per the label, consider Shingrix.
Liver enzymes at baseline if you have known or suspected liver disease.
Triglycerides, periodically. The label asks for periodic evaluation of serum triglycerides. This is the one lab that is specifically called for on an ongoing basis.
Liver enzymes during treatment in anyone with known or suspected liver disease.
Creatine phosphokinase if you have muscle symptoms. CPK rises commonly and usually means nothing. But if you have real muscle pain or weakness, it needs checking, because rhabdomyolysis is a reason to discontinue.
Tuberculosis, about yearly or after a known exposure.
No routine blood count monitoring is required. You will not be having neutrophils, lymphocytes and hemoglobin checked every three months the way you would on Rinvoq or Olumiant, because deucravacitinib does not suppress those counts. If a prescriber tells you Sotyktu needs the full JAK monitoring panel, that is a misunderstanding of what the drug is.
Skin checks annually are sensible given the malignancies reported in trials.
If you have diabetes, watch for hypoglycemia in the first weeks and tell your prescriber if it happens.
Give it four months before you judge it.
Weeks 1 to 4: plaques begin to thin. Most people notice something by week 4.
Weeks 8 to 16: the main improvement. Week 16 is the standard point at which the drug is assessed.
Weeks 16 to 24 and beyond: the response continues to deepen. A meaningful number of people who look like partial responders at 16 weeks are doing distinctly better at 24. This is a slower burn than an IL-17 biologic, so do not abandon it at week 12.
Scalp psoriasis usually improves along with body plaques. Nail psoriasis takes far longer — six months to a year — because the nail must grow out.
Psoriatic arthritis joint symptoms typically improve over the first few months.
Be realistic about the ceiling. Sotyktu clears skin substantially better than Otezla and it beats a placebo comfortably, but it does not match the injectable IL-23 and IL-17 biologics for complete clearance. Plenty of people get skin they are genuinely happy with; fewer get completely clear skin than would on Skyrizi. If you are trading a small amount of efficacy for a pill with no boxed warning and no monthly labs, that is a reasonable trade — just make it knowingly.
Sotyktu controls psoriasis; it does not cure it.
It is a small molecule and it clears from your body within days, unlike a biologic antibody that lingers for weeks. So the protective effect fades faster. Most people see plaques returning over several weeks to a few months after stopping.
There is no dangerous rebound of the kind that follows stopping oral steroids — psoriasis generally returns to roughly the severity you had before rather than flaring worse. But the return is noticeable enough that you should plan a stop rather than just running out of tablets.
If you restart later, it works again. There are no antibodies to build up against a small molecule, which is an advantage over the injectable biologics.
If you have to pause for an infection or surgery, that is straightforward — stop, treat, restart when things have settled.
If you stop because it is not clearing you enough, the usual next step is an injectable biologic: Skyrizi, Tremfya or Cosentyx all clear skin more completely. If you stop because of cost, ask about the manufacturer program and about appeals before you give up on it.